134 related articles for article (PubMed ID: 37919600)
1. A Risk-Based Approach for Safety Case Follow-up of Adverse Event Reports in Pharmacovigilance.
Vemula GK; Badale P; Mavrogenis P; Lalande-Luesink I; Borkowski M; Lewis DJ
Adv Ther; 2024 Jan; 41(1):82-91. PubMed ID: 37919600
[TBL] [Abstract][Full Text] [Related]
2. Impact of adverse event reports from marketing authorization holder-sponsored patient support programs on the performance of signal detection in pharmacovigilance.
Lee I; Lee TA; Crawford SY; Kilpatrick RD; Calip GS; Jokinen JD
Expert Opin Drug Saf; 2020 Oct; 19(10):1357-1366. PubMed ID: 32662668
[TBL] [Abstract][Full Text] [Related]
3. Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks.
van Stekelenborg J; Kara V; Haack R; Vogel U; Garg A; Krupp M; Gofman K; Dreyfus B; Hauben M; Bate A
Drug Saf; 2023 Jan; 46(1):39-52. PubMed ID: 36565374
[TBL] [Abstract][Full Text] [Related]
4. Sorting Through the Safety Data Haystack: Using Machine Learning to Identify Individual Case Safety Reports in Social-Digital Media.
Comfort S; Perera S; Hudson Z; Dorrell D; Meireis S; Nagarajan M; Ramakrishnan C; Fine J
Drug Saf; 2018 Jun; 41(6):579-590. PubMed ID: 29446035
[TBL] [Abstract][Full Text] [Related]
5. Bulgarian Experience with Adverse Drug Reaction Reports from Patients and Consumers - Retrospective Data-base Study.
Getova VI; Georgiev SR; Stoimenova AH; Petkova-Georgieva ES
Folia Med (Plovdiv); 2018 Sep; 60(3):447-453. PubMed ID: 30355838
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
7. Exploring Completeness of Adverse Event Reports as a Tool for Signal Detection in Pharmacovigilance.
Lee I; Jokinen JD; Crawford SY; Calip GS; Kilpatrick RD; Lee TA
Ther Innov Regul Sci; 2021 Jan; 55(1):142-151. PubMed ID: 32720297
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of completeness of suspected adverse drug reaction reports submitted to the mexican national pharmacovigilance centre: a cross-sectional period-prevalence study.
Sánchez-Sánchez B; Altagracia-Martínez M; Kravzov-Jinich J; Moreno-Bonett C; Vázquez-Moreno E; Martínez-Núñez JM
Drug Saf; 2012 Oct; 35(10):837-44. PubMed ID: 22924896
[TBL] [Abstract][Full Text] [Related]
9. Automation Opportunities in Pharmacovigilance: An Industry Survey.
Ghosh R; Kempf D; Pufko A; Barrios Martinez LF; Davis CM; Sethi S
Pharmaceut Med; 2020 Feb; 34(1):7-18. PubMed ID: 32036574
[TBL] [Abstract][Full Text] [Related]
10. Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility.
Muñoz MA; Dal Pan GJ; Wei YJ; Delcher C; Xiao H; Kortepeter CM; Winterstein AG
Drug Saf; 2020 Apr; 43(4):329-338. PubMed ID: 31912439
[TBL] [Abstract][Full Text] [Related]
11. The Enigma of Pharmacovigilance of Patient Support Programs: A Survey of Marketing Authorization Holders in Europe.
Portnoff JM; Lewis DJ
Ther Innov Regul Sci; 2017 Jul; 51(4):486-493. PubMed ID: 30227052
[TBL] [Abstract][Full Text] [Related]
12. Application of Augmented Intelligence for Pharmacovigilance Case Seriousness Determination.
Routray R; Tetarenko N; Abu-Assal C; Mockute R; Assuncao B; Chen H; Bao S; Danysz K; Desai S; Cicirello S; Willis V; Alford SH; Krishnamurthy V; Mingle E
Drug Saf; 2020 Jan; 43(1):57-66. PubMed ID: 31605285
[TBL] [Abstract][Full Text] [Related]
13. Development of a multivariate prediction model to identify individual case safety reports which require clinical review.
Gosselt HR; Bazelmans EA; Lieber T; van Hunsel FPAM; Härmark L
Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1300-1307. PubMed ID: 36251280
[TBL] [Abstract][Full Text] [Related]
14. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
Castillon G; Salvo F; Moride Y
Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742
[TBL] [Abstract][Full Text] [Related]
15. Pharmacovigilance in Israel - tools, processes, and actions.
Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
[TBL] [Abstract][Full Text] [Related]
16. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
[TBL] [Abstract][Full Text] [Related]
17. Safety of clozapine use during pregnancy: Analysis of international pharmacovigilance data.
Beex-Oosterhuis MM; Samb A; Heerdink ER; Souverein PC; Van Gool AR; Meyboom RHB; van Marum RJ
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):725-735. PubMed ID: 32378285
[TBL] [Abstract][Full Text] [Related]
18. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
[TBL] [Abstract][Full Text] [Related]
19. Dispositions and Causality Assessment in Pharmacovigilance: Proposing the Dx3 Approach for Assessing Causality with Small Data Sets.
Anjum RL; Chandler RE; Rocca E
Pharmaceut Med; 2022 Jun; 36(3):153-161. PubMed ID: 35486326
[TBL] [Abstract][Full Text] [Related]
20. Completeness of published case reports on suspected adverse drug reactions: evaluation of 100 reports from a company safety database.
Impicciatore P; Mucci M
Drug Saf; 2010 Sep; 33(9):765-73. PubMed ID: 20701409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
